According to preliminary research, phosphate binders may bind to helpful substances such as vitamin K, but also to harmful ones, such as lipopolysaccharides and advanced glycation end products.
In meta-analyses, elevated FGF23 correlated with 25% and 22% increased risks for all-cause mortality and cardiovascular events, respectively, among patients on maintenance hemodialysis.
In a phase 3 trial, tenapanor, which reduces paracellular phosphate transport in the intestine, lowered elevated serum phosphorus in patients on hemodialysis.
In a new study, patients with serum phosphate levels above 1.78 mmol/L at the start of peritoneal dialysis had a nearly 2-fold increased risk of death.
In a 2-phased trial, hyperphosphatemia and is sequelae developed in a smaller proportion of patients taking activated charcoal compared with placebo recipients.
In 2 studies, roughly a third of hemodialysis patients achieved within-range serum phosphate levels after converting to sucroferric oxyhydroxide from another phosphate binder.
In a small study of hemodialysis patients, substituting egg white for meat and fish in 3 meals per week resulted in a significant decrease in serum phosphate.
